email article
Treatment with the investigational monoclonal antibody mavrilimumab significantly improved outcomes among patients with severe COVID-19 also given standard of care treatment, an international phase II randomized trial found.
Among patients who were not on mechanical ventilation at the time of study enrollment, but had severe COVID-19 with hyperinflammation, those given one of two doses of mavrilimumab had a 65% lower risk of mechanical ventilation or death by day 29, reported Lara Pupim, MD, of Kiniksa Pharmaceuticals in Lexington, Massachusetts.
Compared with patients given placebo, those on mavrilimumab also had a 61% reduction in risk of death at day 29, she reported during a late-breaking session of the European League Against Rheumatism virtual meeting.